Accurate and Rapid Diagnosis of Myocardial Infarction Using a High-Sensitivity Troponin I 1-Hour Algorithm Johannes Tobias Neumann1, Nils Arne Sörensen1,

Slides:



Advertisements
Similar presentations
Tobias Reichlin, W. Hochholzer, C. Stelzig, K. Laule, M. Potocki, K
Advertisements

for the TRAPID-AMI Investigators
Connie N. Hess, MD, Bimal R. Shah, MD, MBA, S. Andrew Peng, MS, Laine Thomas, PhD, Matthew T. Roe, MD, MHS, Eric D. Peterson, MD, MPH Relationship of Early.
Journal Club Mohammed AlShamsi R4
Copeptin and high sensitive Troponins Discussion of NEJM publications on sensitive Troponins BRAHMS GmbH, August 2010.
Procalcitonin Over the past two decades, the body of literature on the clinical usefulness of procalcitonin (PCT) in adults has grown rapidly. Although.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence May–June 2010.
High Sensitivity Troponin
Overly concerning and falsely reassuring?? FRAMINGHAM RISK FACTORS IN THE ED.
Body Weight and Mortality: New Population Based Evidences Body Weight and Mortality: New Population Based Evidences Dongfeng Gu, MD Dongfeng Gu, MD Fu.
Only You Can Prevent CVD Matthew Johnson, MD. What can we do to prevent CVD?
Anterior Depressions Angiographic and Clinical Outcomes Among Patients with Acute Coronary Syndromes Presenting with Anterior ST-Segment Depressions C.
Development of Clinical Pathways to Streamline Care for Patients Presenting with Suspected Cardiac Chest Pain Background The National Heart Foundation.
Emily O’Brien, Emil Fosbol, Andrew Peng, Karen Alexander, Matthew Roe, Eric Peterson The Obesity Paradox: The Importance for Long-term Outcomes in Non-ST-Elevation.
Statistics in Screening/Diagnosis
Around-the-Clock Primary Angioplasty: A Process of Care Analysis Comparing Off-Hours and Normal Hours Treatment of Acute STEMI R Leung, D Lundberg, D Galbraith,
PPAR  activation Clinical evidence. Evolution of clinical evidence supporting PPAR  activation and beyond Surrogate outcomes studies Large.
A 2-hour Accelerated Diagnostic Protocol to Assess Patients With Chest Pain Symptoms Using Contemporary Troponins as the Only Bbiomarker (ADAPT) Martin.
Sex-Specific Chest Pain Characteristics in AMI Jay Mansfield, Pgy-3 July 22, 2014 LSU Journal Club Gimenez, M, et. Al. Jama Int Med. 2014;174(2):
Please press F5 on your keyboard to enter presentation mode Welcome to the Eastern Health Pathology guide to hsTnT. The information in this presentation.
Naotsugu Oyama, MD, PhD, MBA A Trial of PLATelet inhibition and Patient Outcomes.
Absolute and Relative Kinetic Changes of High-Sensitivity Cardiac Troponin T in Acute Coronary Syndrome and in Patients with Increased Troponin in the.
Introduction Left bundle branch block (LBBB) is notorious for obscuring the ECG diagnosis of acute myocardial infarction (AMI) and, therefore, the decision.
Atypical Presentations Patients older than 75: frequently no chest pain ECG in evolution (nonspecific ECG changes) Diabetic patients: commonly no chest.
Journal Club Optimizing Early Rule-Out Strategies for Acute Myocardial Infarction: Utility of 1-Hour Copeptin P. Hillinger, R. Twerenbold, C. Jaeger, K.
Validation and Refinement of a Prediction Rule to Identify Children at Low Risk for Acute Appendicitis Kharbanda AB, Dudley NC, Bajaj L, et al; Pediatric.
1 EFFICACY OF SHORT COURSE AMOXICILLIN FOR NON-SEVERE PNEUMONIA IN CHILDREN (Hazir T*, Latif E*, Qazi S** AND MASCOT Study Group) *Children’s Hospital,
Trends in the Quality of Care of Patients with Acute Myocardial Infarction: The National Registry of Myocardial Infarction from 1990 to 2006 Bimal R. Shah,
Implementation of a Sensitive Troponin I Assay and Risk of Recurrent Myocardial Infarction and Death in Patients With Suspected Acute Coronary Syndrome.
RESEARCH POSTER PRESENTATION DESIGN © Cardiac Troponin Assay Cardiac troponin I is the diagnostic marker used for myocardial.
Which troponin assay to choose? Clinical performances of troponin T and troponin I assays Per Venge, MD PhD Professor Department of Medical Sciences Uppsala.
Peripheral Artery Disease in Orthopaedic Patients with Asymptomatic Popliteal Artery Calcification on Plain X-ray Adam Podet, MS; Julia Volaufova, phD,;
TAHAR EL KANDOUSSI, SARA ECHERKI, NAWAL DOGHMI, MOHAMED CHERTI. SEcurite de l’Echocardiographie de stress : plutôt l’effort. Cardiology B Department, Ibn.
Troponin By Julie Moore C Dt204/2.
Effect of Thrombus Aspiration in Patients With Myocardial Infarction Presenting Late After Symptom Onset Steffen Desch, MD Thomas Stiermaier, MD; Suzanne.
Date of download: 7/5/2016 Copyright © 2016 American Medical Association. All rights reserved. From: One-Hour Rule-out and Rule-in of Acute Myocardial.
1 Predictors of virological failure in a Cambodian setting Sokkab An, M.D Sihanouk Hospital Center of HOPE (SHCH), Phnom Penh, Cambodia.
Associate Professor, Honorary Consultant Cardiologist
External multicentric validation of a COPD detection questionnaire.
Evaluation of CT Coronary Angiography (CTCA) and Cardiac Magnetic Resonance (CMR) in patients presenting with Acute Chest Pain (ACP) at A&E Background.
A Clinical profile of patients enrolled in the Pakistan ACS registry
Prof. Dr. med. Sigmund Silber Cardiology Practice and Hospital
Myocardial Injury after Noncardiac Surgery and Association with Short Term Mortality Wilton A van Klei Anesthesiologist and acting chair Department Anesthesiology,
Risk Stratification of Chest Pain: Best Practices
. Troponin limit of detection plus cardiac risk stratification scores for the exclusion of myocardial infarction and 30-day adverse cardiac events in ED.
HEART PATHWAY Brian O’Neal, MD
An assessment of correlation between ethnicity and modifiable risk factors in the context of primary prevention of cardiovascular disease Patel PA2,
Evaluation of Patients with chest pain Admitted under General Medicine; Has clinical judgment being taken over by serial troponins? Dr. Samantha Herath.
Tobias Reichlin, M. D. , Willibald Hochholzer, M. D
Diagnostic characteristics and prognoses of primary-care patients referred for clinical exercise testing: a prospective observational study Nilsson G1,
Cost Effective Use of Troponin to Rule Out Acute Coronary Syndrome
Improving Care Processes for Patients with Possible Acute Coronary Syndrome (ICARE-ACS)
College of Nursing ● University of Kentucky ● Lexington, KY
One-hour rule-in and rule-out of acute myocardial infarction using high-sensitivity cardiac troponin I  Cedric Jaeger, MD, Karin Wildi, MD, Raphael Twerenbold,
Improved Outcomes in Patients with Non-ST-Elevation Myocardial Infarction during 20 Years are Related to Implementation of Evidence-based Treatments –
Copyright © 2009 American Medical Association. All rights reserved.
Cardiac Biomarkers.
Identifying Patients Suitable for Discharge After a Single-Presentation High-Sensitivity Troponin Result: A Comparison of Five Established Risk Scores.
Section A: Introduction
European Heart Association Journal 2007 April
Nat. Rev. Cardiol. doi: /nrcardio
Advancing Acute Coronary Syndrome Assessment:
Press Conference Title
Prognostic Value of Undetectable hs Troponin T in Suspected Acute Coronary Syndrome  Mehrshad Vafaie, MD, Anna Slagman, VD, MSc, Martin Möckel, MD, PhD,
Brigham and Women’s Hospital
Undetectable High Sensitivity Cardiac Troponin T Level in the Emergency Department and Risk of Myocardial Infarction Nadia Bandstein, MD; Rickard Ljung,
Early rule-out and rule-in of myocardial infarction using sensitive cardiac Troponin I  Sophie Druey, Karin Wildi, Raphael Twerenbold, Cédric Jaeger, Tobias.
Global Registry of Acute Coronary Events: GRACE
Undetectable High Sensitivity Cardiac Troponin T Level in the Emergency Department and Risk of Myocardial Infarction Nadia Bandstein, MD; Rickard Ljung,
ST-segment elevation myocardial infarction in China from 2001 to 2011 (the China PEACE-Retrospective Acute Myocardial Infarction Study): a retrospective.
Presentation transcript:

Accurate and Rapid Diagnosis of Myocardial Infarction Using a High-Sensitivity Troponin I 1-Hour Algorithm Johannes Tobias Neumann1, Nils Arne Sörensen1, Tjark Schwemer1, Francisco Ojeda1, Rafael Bourry1, Vanessa Sciacca1, Sarina Schäfer1,2, Christoph Waldeyer1, Christoph Sinning1, Thomas Renné3, Martin Than5, Will Parsonage4, Karin Wildi6, Nataliya Makarova1,2, Renate B. Schnabel1,2, Ulf Landmesser7, Christian Mueller6, Louise Cullen4, Jaimi Greenslade4, Tanja Zeller1,2, Stefan Blankenberg1,2, Mahir Karakas1,2, Dirk Westermann1,2 1 Department of General and Interventional Cardiology, University Heart Center Hamburg Eppendorf, Hamburg, Germany 2 German Center for Cardiovascular Research (DZHK), Partner Site Hamburg/Kiel/Lübeck, Hamburg, Germany  3 Institute of Clinical Chemistry and Laboratory Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany 4 Royal Brisbane and Women's Hospital, Department of Emergency Medicine, Brisbane 4006, Australia 5 Christchurch Hospital, Christchurch, New Zealand 6 Department of Cardiology and Cardiovascular Research Institute Basel (CRIB), University Hospital Basel, Switzerland 7 Department of Cardiology, Charite Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany

Conflicts of interest BACC was funded by institutional grants from the University Heart Center in Hamburg, Germany and an unrestricted grant from Abbott Diagnostics. Dirk Westermann: To this presentation: none In general: Unrestricted research support from Bayer and Novartis Speaker/Consulting honoraria from Astra Zeneca, Bayer, Berlin Chemie, Biotronic, Orion, Novartis in the last 3 years.

Background There is clinical need to rapidly and safely rule-in or rule-out acute myocardial infarction (AMI) in patients with acute chest pain in order to 1. initiate fast evidence based treatment for patients with AMI 2. limit overuse of scarce medical resources in the emergency room (ER) discharging patients without acute cardiac conditions. Guidelines recommend1,2 measuring high sensitivity assayed troponins directly after admission and after 3 hours detecting elevated levels based on the 99th percentile of the specific assays together with an increase/decrease. Recent studies (ADAPT (2-hour)3 and APACE (1- hour)4 cohort) challenge current guidelines with intervals shorter than 3 hours. 1 Hamm et al. EHJ 2011 and 2 Thygesen et al. EHJ 2012; 3 Than et al. JACC 2012; 4 Reichlin et al. CMAJ 2015

a) a rapid 1-hour rule-out and rule-in compared to a 3-hours approach Aim of the study To investigate the application of high sensitivity assayed troponin I (TnI) for a) a rapid 1-hour rule-out and rule-in compared to a 3-hours approach b) a lower and more sensitive cut-off value compared to the 99th percentile in the Biomarkers in Acute Cardiovascular Care (BACC) cohort investigating 1,045 patients with acute chest pain.

Study design BACC (n = 1,045) patients with acute chest pain suggestive of AMI: Clinical routine troponin assay and clinical treatment based on ESC guidelines1: 0 hour + clinical judgement, imaging and ECG to establish final diagnosis during the complete hospital stay (NSTEMI vs. no AMI) (as recommended by ESC guidelines1) 3 hours hsTnT hsTnT hsTnT: troponin T assay (Elecsys® troponin T high sensitive, Roche Diagnostics) 1 Hamm et al. EHJ 2011

Study design BACC (n = 1,045) patients with acute chest pain suggestive of AMI: Clinical routine troponin assay and clinical treatment based on ESC guidelines1: 0 hour + clinical judgement, imaging and ECG to establish final diagnosis during the complete hospital stay (NSTEMI vs. no AMI) (as recommended by ESC guidelines1) 3 hours hsTnT hsTnT 1 hour 0 hour hsTnI 3 hours + without adding additional information hsTnT: troponin T assay (Elecsys® troponin T high sensitive, Roche Diagnostics) hsTnI: troponin I assay (STAT high sensitive Troponin I, ARCHITECT i2000SR, Abbott Diagnostics, USA) 1 Hamm et al. EHJ 2011

Study design Calculate best performing cut-off and apply it BACC (n = 1.045) patients with acute chest pain suggestive of AMI: Clinical routine troponin assay and clinical treatment based on ESC guidelines1: 0 hour + clinical judgement, imaging and ECG to establish final diagnosis during the complete hospital stay (NSTEMI vs. no AMI) (as recommended by ESC guidelines1) 3 hours hsTnT hsTnT 1 hour 0 hour hsTnI 3 hours + without adding additional information Calculate best performing cut-off and apply it Validate results in other cohorts Applicate cut-off in general population 1 Hamm et al. EHJ 2011

Statistical methods Baseline characteristics are described by quartiles for continuous variables and by absolute and relative frequencies for categorical variables. For the diagnostic algorithms considered negative and positive predictive values were computed (together with 95% confidence intervals). Equality of predictive values was tested1. 1 Kosinski et al. Stat Med 2013

Baseline data All (N=1,045) NSTEMI (N=184) Non-AMI (N=793) p-value   All (N=1,045) NSTEMI (N=184) Non-AMI (N=793) p-value Demographics Age (years) 65.0 (52.0, 75.0) 70.0 (60.4, 77.0) 64.0 (50.7, 74.0) < 0.001 Male (%) 678 (64.9) 124 (67.4) 505 (63.7) n.s. BMI (kg/m²) 26.0 (23.5, 29.4) 26.2 (23.7, 29.7) Risk Factors Hypertension (%) 731 (70.0) 147 (79.9) 541 (68.2) 0.0017 Hyperlipoproteinemia (%) 459 (43.9) 103 (56.0) 327 (41.2) Diabetes (%) 150 (14.5) 39 (21.3) 102 (12.9) 0.0051 Former smoker (%) 334 (32.0) 59 (32.1) 259 (32.7) Current smoker (%) 241 (23.1) 41 (22.3) 169 (21.3) History of CAD/Bypass/PCI (%) 353 (33.8) 80 (43.5) 255 (32.2) 0.0044 History of AMI (%) 165 (15.8) 41 (22.4) 114 (14.4) 0.0097 STEMI (57) and SAP (11) patients were excluded from the non-AMI group

Best performing cut-off   NSTEMI 1 Cut-off (ng/L) NPV (95% CI) False Negative 3 100.0 (97.1-100.0) 4 99.6 (98.0-100.0) 1 5 99.7 (98.3-100.0) 5,2 (10% coefficient of variation) 99.7 (98.4-100.0) 6 99.7 (98.6-100.0) 7 99.6 (98.4-99.9) 2 8 99.4 (98.3-99.9) 9 99.4 (98.4-99.9) 10 99.3 (98.2-99.8) 15 98.9 (97.8-99.6) 20 98.8 (97.7-99.5) 27 (99th percentile) 98.4 (97.2-99.2) 11

Suggested 1-hour algorithm Rule-out AMI 1h vs. 3h Suggested 1-hour algorithm NSTEMI rule-out: hsTnI  6 ng/L at 0h and 1h resulted in 402 out of 1,045 patients being discharged Cut-off Time after admission NPV NSTEMI 1 (95% CI) Sensitivity NSTEMI 6ng/L 1-hour 99.7 (98.6-100.0) 99.1 (94.9-100.0) 99.0 (97.5-99.7) 97.6 (94.1-99.4) 3-hour 100.0 (98.5-100.0) 99.5 (98.1-99.9) 98.8 (95.8-99.9) p = n.s. vs. 1h p = n.s. vs. 1h NPV: negative predictive value; NSTEMI 1: non STEMI type 1 in view of Thygesen K et al. EHJ 2012

Higher performance of 6 ng/L vs. 27 ng/L Cut-off Time after admission NPV NSTEMI 1 (95% CI) Sensitivity NSTEMI 6 ng/L 1-hour 99.7 (98.6-100.0) 99.1 (94.9-100.0) 99.0 (97.5-99.7) 97.6 (94.1-99.4) 3-hour 100.0 (98.5-100.0) 99.5 (98.1-99.9) 98.8 (95.8-99.9) 27 ng/L (99th percentile) 98.4* (97.2-99.2) 89.6 (82.2-94.7) 94.8* (92.9-96.3) 77.5 (70.5-83.6) 99.1# (98.1-99.7) 94.3 (88.1-97.9) 96.8# (95.3-98.0) 87.1 (81.2-91.8) p < 0.05 for 6 ng/L at * 1h or # 3h NPV: negative predictive value; NSTEMI 1: non STEMI type 1 in view of Thygesen K et al. EHJ 2012

Best performing Rule-In Algorithm Suggested 1-hour algorithm NSTEMI rule-in: hsTnI after 1h > 6 ng/L together with a delta of 12 ng/L to 0h Criteria to diagnose patients as NSTEMI PPV NSTEMI 1 (95% CI) Specificity NSTEMI 1 (95% CI) NSTEMI 1-hour rule-in 82.8 (73.2-90.0) 98.0 (96.7-98.9) 87.1 (79.6-92.6) 3-hour rule-in 78.6 (69.8-85.8) 96.8 (95.2-97.9) 84.6 (78.0-89.9) p = n.s. vs. 1h p = n.s. vs. 1h PPV: positive predictive value; NSTEMI 1: non STEMI type 1 in view of Thygesen K et al. EHJ 2012

Validation in 2 independent cohorts Rule used to diagnose all NSTEMI   ADAPT (2-hour) APACE (1-hour) Non-AMI NSTEMI Number of patients 1,499 249 1,832 429 Age, years, Median 59 (49-70) 71 (60-79) 59 (47-73) 72 (59-80) Male gender (%) 868 (57.9) 163 (65.5) 1,226 (66.9) 316 (73.7) Rule used to diagnose all NSTEMI NPV for rule-out PPV for rule-in (95% CI) Troponin I APACE1 Rule-out algorithm ( 6 ng/L and after 1h  6 ng/L) 99.2 (98.4-99.6) Rule-in algorithm (1h > 6 ng/L and ≥ 12 ng/L) 80.4 (75.1-84.9) Troponin I ADAPT2 ( 6 ng/L and after 2h  6 ng/L) 99.7 (99.2-99.9) 81.5 (75.8-86.3) 1 Reichlin et al. CMAJ 2015, 2 Than et al. JACC 2012

Suggested 1-hour algorithm Follow-up mortality Suggested 1-hour algorithm NSTEMI rule-out: hsTnI  6 ng/L at 0h and 1h NSTEMI rule-in: hsTnI after 1h > 6 ng/L and a delta of 12 ng/L to 0h Greyzone: Patients not identified by both algorithms (elevated but stable TnI values) 3 of 1,045 patients lost to follow-up: median 183 days (41,2%) patients Mortality (11,9%) patients (46,9%) patients 6 months

Follow-up mortality Rule-out 6 ng/L 27 ng/L (99th percentile) 6 months mortality 3 deaths (0.79%) 12 deaths (1.73%) * (41,2%) patients Mortality (11,9%) patients (46,9%) patients 6 months 3 of 1,045 patients lost to follow-up: median 183 days * p>0.05 vs 6 ng/L

Follow-up mortality in 74,738 individuals (aged 51.0 years (42-60)) of the general population without prevalent CVD with follow up for cardiovascular mortality. P<0.001 P<0.001 1 year 206 events 32 events Survival Survival 423 events 70 events 1 year follow-up 5 years follow-up

Conclusion A 1-hour algorithm is safe to rule-out AMI. A sensitive troponin I cut-off (6 ng/L) performed better compared to the 99th percentile (27 ng/L) in view of lower follow-up mortality. Low troponin I values predict mortality in the general population. Further studies are needed to test the best cut-off for each troponin assay and to validate a 1-hour algorithm prospectively.

Acknowledgement To the patients included in the BACC, ADAPT and APACE cohorts. To the individuals of the BiomarCaRE cohort. To the study teams involved in all cohorts and trials